Related Experiment Video
Updated: Apr 27, 2026
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Systematic immunohistochemical analysis of the expression of CD46, CD55, and CD59 in colon cancer
Yulong Shang1, Na Chai, Yong Gu
1From the State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases (Drs Shang, Chai, Zhou, Ren, Fan, Wu, and Nie and Mr Gu, Mss Ding and Yang), and the Department of Medical Laboratory, Xijing Hospital (Dr Hao and Ms Ding), Fourth Military Medical University, and the Department of Digestive Diseases, Shaanxi Provincial Corps Hospital of Chinese People's Armed Police Force (Mr Gu), Xi'an, China. Drs Shang, Chai, and Mr Gu contributed equally to this article.
Context:
The expression of membrane-bound complement regulatory proteins (mCRPs) that inhibit the complement system in normal tissues is essential for self-protection against an autologous immune reaction. However, the expression patterns of mCRPs, including CD46, CD55, and CD59, are inconsistent in different types of cancer cells.
Objectives:
To determine whether CD46, CD55, and CD59 are differentially expressed in neoplastic and adjacent normal colon tissues and to assess their clinical significance.
Design:
Immunohistochemistry was performed on tissue microarrays of cancerous and adjacent normal colon tissues.
Results:
The expression levels of CD46, CD55, and CD59 were significantly higher in colon cancer tissues compared with the normal adjacent colon tissues. We found that the expression levels of CD55 and CD59 correlated with the grade of differentiation in colon cancers. In addition, the expression of CD55 and CD59 was greater in stage III and stage IV colon cancers than in stage I and stage II cancers according to staging by the TNM classification.
Conclusions:
CD46, CD55, and CD59 are up-regulated in colon cancer. Specifically, CD55 and CD59 are of clinical relevance to differentiation and TNM staging of colon cancer. These data suggest that CD46, CD55, and CD59 have the potential to be used for molecular staging diagnoses and for colon cancer therapies.
Insights
Membrane-bound complement regulatory proteins (mCRPs) like CD46, CD55, and CD59 are elevated in colon cancer tissues. CD55 and CD59 expression correlates with cancer differentiation and stage, suggesting their potential as biomarkers.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Membrane-bound complement regulatory proteins (mCRPs) are crucial for preventing autoimmune reactions by inhibiting the complement system.
- Expression patterns of mCRPs, including CD46, CD55, and CD59, vary significantly across different cancer types.
- Understanding mCRP expression in cancer is vital for developing targeted therapies and diagnostic markers.
Purpose of the Study:
- To investigate the differential expression of CD46, CD55, and CD59 in colon cancer tissues compared to adjacent normal tissues.
- To evaluate the clinical significance of CD46, CD55, and CD59 expression in relation to colon cancer differentiation and staging.
Main Methods:
- Tissue microarrays were constructed from cancerous and adjacent normal colon tissues.
- Immunohistochemistry was employed to quantify the expression levels of CD46, CD55, and CD59.
- Statistical analysis was performed to correlate protein expression with clinical parameters such as differentiation grade and TNM stage.
Main Results:
- CD46, CD55, and CD59 expression levels were significantly upregulated in colon cancer tissues relative to normal adjacent tissues.
- Expression of CD55 and CD59 demonstrated a correlation with the grade of differentiation in colon cancers.
- Advanced stages of colon cancer (Stage III and IV) exhibited higher expression of CD55 and CD59 compared to earlier stages (Stage I and II) based on TNM classification.
Conclusions:
- CD46, CD55, and CD59 are consistently upregulated in the context of colon cancer.
- CD55 and CD59 expression levels hold clinical relevance for assessing colon cancer differentiation and TNM staging.
- These findings highlight the potential utility of CD46, CD55, and CD59 as targets for molecular staging and therapeutic interventions in colon cancer.
More Related Videos
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
06:05Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment
Published on: June 2, 2023